THALES
Powered by the cutting-edge technologies and products of Thales and Verint, the two companies are pleased to present The Cyberthreat Handbook , a report of unprecedented scope designed to provide a classification and basis for further investigation of major groups of cyberattackers, including cybercriminals, cyberterrorists, hacktivist groups and state-sponsored hackers. As part of the strategic partnership to create a comprehensive, state-of-the art Cyber Threat Intelligence technologies, threat intelligence analysts from Thales and Verint have worked together to provide this unique 360° view of the cyberthreat landscape, with detailed descriptions of the activities of about sixty particularly significant groups, including their tactics and techniques, their motives and the sectors targeted from analysis of multiple data sources such as web and threat intelligence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191006005044/en/
As cybersecurity grows in importance, Thales and Verint have worked together to find out more about cyberattackers and the techniques they employ, the purpose being to help organisations in the private and public sectors to better detect and anticipate future attacks. The cyberthreat landscape is extremely diversified, and knowing one's enemies can be particularly complex in this world of subterfuge and deception.
"The Thales and Verint teams are immensely proud to release this report today as part of its technology and domain expertise cooperation. Unique in its breadth and depth, it is the culmination of many months of research, investigation and painstaking analysis and correlation of relevant data. As cyberthreats proliferate and evolve, cybersecurity clearly has a major role to play, particularly for critical infrastructure providers. It is our duty to analyse, understand and describe the techniques employed by cyberattackers so that our customers and all other businesses and organisations are better prepared to detect and anticipate future attacks." Marc Darmon, Executive Vice President, Secure Communications and Information Systems, Thales
“Joining forces with Thales strengthens our mutual ability to deliver comprehensive knowledge of potential threats, and thus provide the necessary cyber security protection,” said Elad Sharon, President, Verint Cyber Intelligence Solutions. “Verint Cyber Intelligence leverages years of intelligence domain expertise, embedded within investigation methodologies and technologies critical to prevent cyber-attacks before they get into the gateway of the organization. This report generates unique insights and knowldege to cyber and security experts to mitigate and foresee cyberattacks”.
Analysts from Thales and Verint have defined four major categories of attackers based on their motives and ultimate objectives. Out of approximately sixty major groups of attackers analysed, 49% are state-sponsored groups often aiming to steal sensitive data from targets of geopolitical interest. 26% are ideologically motivated hacktivists, closely followed by cybercriminals (20%) who are driven by financial gain. In fourth position, cyberterrorists account for 5% of the groups analysed.
All the world's major economic, political and military powers are priority targets of cyberattackers. The 12 countries in the world with the highest GDP are all at the top of the list of targets, headed by the United States, Russia, the European Union (particularly the United Kingdom, France and Germany) and China, followed by India, South Korea and Japan.
The sectors most targeted by these major attacks are States and their defence capabilities, followed by the financial sector, energy and transportation. Attacks towards medias and health industry are increasing fast.
Last but not least, a growing number of groups of attackers are now focusing on vulnerabilities in the supply chain, and in particular on smaller partners, suppliers and service providers that are used as trojans to access major targets.
Notes to editors - Methodology This report does not set out to be an exhaustive inventory of cyberattackers but rather to shed light on the major groups of attackers that have been identified over the last 10 years. The sixty-odd groups and 490 attack campaigns analysed in the report were selected because they are considered emblematic in terms of their impact, attack techniques, scope, target profiles, historical nature or recent emergence. The entire analysis is based on the MITRE Att&ck matrix , a knowledge base of adversary tactics and techniques. More details can be found in the press kit.
About Thales Thales (Euronext Paris: HO) is a global technology leader shaping the world of tomorrow today. The Group provides solutions, services and products to customers in the aeronautics, space, transport, digital identity and security, and defence markets. With 80,000 employees in 68 countries, Thales generated sales of €19 billion in 2018 (on a pro forma basis including Gemalto).
Thales is investing in particular in digital innovations — connectivity, Big Data, artificial intelligence and cybersecurity — technologies that support businesses, organisations and governments in their decisive moments
About Verint Systems Inc. Verint® (Nasdaq: VRNT) is a global leader in Actionable Intelligence® solutions with a focus on customer engagement optimisation, security intelligence, and fraud, risk and compliance. Today, over 10,000 organisations in more than 180 countries—including over 80 percent of the Fortune 100—count on intelligence from Verint solutions to make more informed, effective and timely decisions. Learn more about how we’re creating A Smarter World with Actionable Intelligence® at www.verint.com .
About Verint Cyber Intelligence. Verint Cyber Intelligence is a leading global provider of security and intelligence data mining software. Our broad and deep product portfolio is deployed in over 100 countries, helping government, critical infrastructure and enterprise organizations to neutralize and prevent terror, crime and cyber threats for a safer world. |
PLEASE VISIT
Thales Group
Download photos
Download the report
View source version on businesswire.com: https://www.businesswire.com/news/home/20191006005044/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
